Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

FENNEC PHARMACEUTICALS INC. (FENC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2023 4 RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Sold 673 shares @ $7.85, valued at $5.3k
08/18/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 4 Haigh Adrian (COO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Granted 200,000 options @ $8.03, valued at $1.6M
08/07/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment and Duties.",
"FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
08/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment and Duties.",
"FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
08/04/2023 8-K Quarterly results
Docs: "FENNEC PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE"
07/24/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/24/2023 144 Form 144 - Report of proposed sale of securities:
07/06/2023 4 RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Sold 2,207 shares @ $8.47, valued at $18.7k
Exercised 5,208 options to buy @ $0.96, valued at $5k
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 4 Andrade Robert (CFO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Sold 10,000 shares @ $8.99, valued at $89.9k
Sold 7,500 shares @ $8.97, valued at $67.3k
Sold 7,500 shares @ $8.82, valued at $66.2k
Exercised 25,000 options to buy @ $2.45, valued at $61.3k
06/29/2023 144 Form 144 - Report of proposed sale of securities:
06/28/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients"
05/19/2023 4 RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Sold 833 shares @ $7.36, valued at $6.1k
Sold 925 shares @ $7.36, valued at $6.8k
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/17/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients"
04/03/2023 4 Andrade Robert (CFO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Granted 75,000 options to buy @ $8.32, valued at $624k
Granted 37,500 options to buy @ $0
04/03/2023 4 Raykov Rosty (CEO) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Granted 175,000 options to buy @ $8.32, valued at $1.5M
Granted 87,500 options to buy @ $0
03/29/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A Sonic GP LLC reports a 9.8% stake in Fennec Pharmaceuticals Inc.
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Fennec Pharmaceuticals Announces PEDMARK Receives Orphan Drug Exclusivity from U.S. FDA"
01/25/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients"
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/30/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/13/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/01/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/17/2022 4 RALLIS CHRIS A (Director) has filed a Form 4 on FENNEC PHARMACEUTICALS INC.
Txns: Sold 333 shares @ $7.99, valued at $2.7k
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy